Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.
Omar NB, Bentley RT, Crossman DK, Foote JB, Koehler JW, Markert JM, Platt SR, Rissi DR, Shores A, Sorjonen D, Yanke AB, Gillespie GY, Chambers MR. Omar NB, et al. Among authors: gillespie gy. Neurosurg Focus. 2021 Feb;50(2):E5. doi: 10.3171/2020.11.FOCUS20844. Neurosurg Focus. 2021. PMID: 33524948 Free PMC article.
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
Patel DM, Foreman PM, Nabors LB, Riley KO, Gillespie GY, Markert JM. Patel DM, et al. Among authors: gillespie gy. Hum Gene Ther Clin Dev. 2016 Jun;27(2):69-78. doi: 10.1089/humc.2016.031. Hum Gene Ther Clin Dev. 2016. PMID: 27314913 Free PMC article. Clinical Trial.
The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas.
Chambers MR, Bentley RT, Crossman DK, Foote JB, Koehler JW, Markert JM, Omar NB, Platt SR, Self DM, Shores A, Sorjonen DC, Waters AM, Yanke AB, Gillespie GY. Chambers MR, et al. Among authors: gillespie gy. Front Surg. 2020 Aug 28;7:59. doi: 10.3389/fsurg.2020.00059. eCollection 2020. Front Surg. 2020. PMID: 33005623 Free PMC article.
Oncolytic HSV-1 for the treatment of brain tumours.
Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ. Markert JM, et al. Among authors: gillespie gy. Herpes. 2006 Nov;13(3):66-71. Herpes. 2006. PMID: 17147910 Review.
Herpes simplex virus oncolytic therapy for pediatric malignancies.
Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY. Friedman GK, et al. Among authors: gillespie gy. Mol Ther. 2009 Jul;17(7):1125-35. doi: 10.1038/mt.2009.73. Epub 2009 Apr 14. Mol Ther. 2009. PMID: 19367259 Free PMC article. Review.
Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.
Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, Peggins JO, Noker PE, Powers NW, Grimes SD, Carroll SL, Gillespie GY, Whitley RJ, Markert JM. Roth JC, et al. Among authors: gillespie gy. Hum Gene Ther Clin Dev. 2014 Mar;25(1):16-27. doi: 10.1089/humc.2013.201. Hum Gene Ther Clin Dev. 2014. PMID: 24649838 Free PMC article.
Genetically engineered HSV in the treatment of glioma: a review.
Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ. Markert JM, et al. Among authors: gillespie gy. Rev Med Virol. 2000 Jan-Feb;10(1):17-30. doi: 10.1002/(sici)1099-1654(200001/02)10:1<17::aid-rmv258>3.0.co;2-g. Rev Med Virol. 2000. PMID: 10654002 Review.
295 results